On Mar. 1, 2021, Quidel announced that it had received an Emergency Use Authorization (EUA) from the FDA, allowing the company to market its new QuickVue At-Home COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2.

This test was authorized for prescription home use with self-collected (unobserved) anterior nares (NS) swab specimens directly from individuals aged 14 years and older who are suspected of COVID-19 by their healthcare provider within the first six days of the onset of symptoms.